TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Nonoperating Income (Expense) USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Nonoperating Income (Expense) history and growth rate from 2010 to 2024.
  • Teva Pharmaceutical Industries Ltd Nonoperating Income (Expense) for the quarter ending March 31, 2024 was -$250 M, a 3.85% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was -$1.05 B, a 8.16% decline year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Nonoperating Income (Expense) for 2023 was -$1.06 B, a 9.42% decline from 2022.
  • Teva Pharmaceutical Industries Ltd annual Nonoperating Income (Expense) for 2022 was -$966 M, a 8.7% increase from 2021.
  • Teva Pharmaceutical Industries Ltd annual Nonoperating Income (Expense) for 2021 was -$1.06 B, a 26.9% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$1.05 B -$250 M +$10 M +3.85% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$1.06 B -$249 M -$4 M -1.63% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 -$1.05 B -$280 M -$28 M -11.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$1.03 B -$268 M -$57 M -27% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 -$968 M -$260 M -$2 M -0.78% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$966 M -$245 M +$8 M +3.16% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$974 M -$252 M -$11 M -4.56% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$963 M -$211 M +$63 M +23% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$1.03 B -$258 M +$32 M +11% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$1.06 B -$253 M +$17 M +6.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 -$1.08 B -$241 M -$124 M -106% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$951 M -$274 M -$51 M -22.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$900 M -$290 M -$66 M -29.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$834 M -$270 M -$83 M -44.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 -$751 M -$117 M +$94 M +44.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 -$845 M -$223 M -$17 M -8.25% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$828 M -$224 M -$6 M -2.75% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$822 M -$187 M +$36 M +16.1% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 -$858 M -$211 M +$18 M +7.86% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$876 M -$206 M +$30 M +12.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$906 M -$218 M +$53 M +19.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$959 M -$223 M -$32 M -16.8% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 -$927 M -$229 M +$30 M +11.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$957 M -$236 M +$2 M +0.84% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$959 M -$271 M -$64 M -30.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$895 M -$191 M +$586 M +75.4% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 -$1.48 B -$259 M -$109 M -72.7% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 -$1.37 B -$238 M -$133 M -127% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$1.24 B -$207 M +$91 M +30.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 -$1.33 B -$777 M -$707 M -1010% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 -$623 M -$150 M +$547 M +78.5% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 -$1.17 B -$105 M -$64 M -156% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 -$1.11 B -$298 M -$106 M -55.2% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 -$1 B -$70 M $0 0% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 -$1 B -$697 M -$613 M -730% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 -$387 M -$41 M +$37 M +47.4% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 -$424 M -$192 M -$111 M -137% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 -$313 M -$70 M -$11 M -18.6% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 -$302 M -$84 M -$8 M -10.5% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 -$294 M -$78 M +$11 M +12.4% Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 -$305 M -$81 M +$94 M +53.7% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 -$399 M -$59 M +$87 M +59.6% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 -$486 M -$76 M -$3 M -4.11% Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 -$483 M -$89 M +$8 M +8.25% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 -$491 M -$175 M -$105 M -150% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 -$386 M -$146 M -$78 M -115% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 -$308 M -$73 M -$6 M -8.96% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 -$302 M -$97 M -$117 M -585% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 -$185 M -$70 M -$32 M -84.2% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 -$153 M -$68 M -$21 M -44.7% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 -$132 M -$67 M -$64 M -2133% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 -$68 M $20 M +$168 M Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 -$236 M -$38 M -$11 M -40.7% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 -$225 M -$47 M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 -$3 M Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 -$148 M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 -$27 M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.